TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3535008

Group type: EXPERIMENTAL
Intervention: Ketanserin, 40‐160 mg daily
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30908369

Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC) - 3 × 5 minutes at 220 mm Hg in both arms with 5-minute rests
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham Intervention (SHAM) - occlusion pressure set at 10 mm Hg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC)
Number of subjects: 16
Study: 31106659

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid group: 2 omega-3 fatty acid capsules (330 mg each) daily + vitamin D3 placebo weekly
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Vitamin D group: 50,000 IU vitamin D3 soft gel weekly + 2 omega-3 fatty acid placebo capsules daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cosupplementation group: 50,000 IU vitamin D3 soft gel weekly + 2 omega-3 fatty acids capsules daily for 8 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group: vitamin D3 placebo weekly + omega-3 fatty acid placebo capsules daily
Number of subjects: 81
Study: 29494787

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation program (n = 42)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Wait-list control group (n = 39)
Number of subjects: 81
Study: 27751554

Group type: EXPERIMENTAL
Intervention: MIS plus alteplase (0.3 mg or 1.0 mg every 8 hours for up to nine doses)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 96
Study: 24851847

Group type: EXPERIMENTAL
Intervention: Balneotherapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Resting Control
Number of subjects: 49
Study: 22495940

Group type: EXPERIMENTAL
Intervention: COMET + therapy as usual (TAU)
Number of subjects: 61

Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 61
Study: 20374035

Group type: EXPERIMENTAL
Intervention: Rhodiola algida mixture consumed for 14 consecutive days after each cycle of chemotherapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: 0.2% chlorohexidine mouth wash used every day
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Rhodiola algida mixture
Number of subjects: 130
Study: 18389895

Group type: EXPERIMENTAL
Intervention: Tipranavir boosted with ritonavir (TPV/r)
Number of subjects: 984

Group type: COMPARATOR
Intervention: Comparator ritonavir‐boosted protease inhibitor (CPI/r)
Number of subjects: 984
Study: 16288157

Group type: EXPERIMENTAL
Intervention: Exercise program (45-50 minutes, twice a week for 8 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 46
Study: 12033654

Group type: EXPERIMENTAL
Intervention: Buprenorphine (Subutex)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 11414432

Group type: EXPERIMENTAL
Intervention: Artesunate 200 mg once daily for 3 days
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Artesunate 200 mg together with mefloquine 10 mg/kg on the first 2 days and artesunate 200 mg together with mefloquine 5 mg/kg on the third day
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Artesunate 200 mg together with azithromycin 50 mg once daily for 3 days
Number of subjects: 202
Study: 9339615

Group type: EXPERIMENTAL
Intervention: Positive suggestion via headphones during anaesthetic period
Number of subjects: 50

Group type: COMPARATOR
Intervention: Blank tape played during anaesthetic period (Control)
Number of subjects: 50
Study: 8439637

Group type: EXPERIMENTAL
Intervention: Early nizatidine (300 mg) with early supper (18.00 hours)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Late nizatidine (300 mg) with late supper (21.00 hours)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Early nizatidine (300 mg) with late supper (21.00 hours)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo with early supper (18.00 hours)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo with late supper (21.00 hours)
Number of subjects: 11
Study: 3755791

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine and Pirenzepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31090059

Group type: EXPERIMENTAL
Intervention: Implants
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Intra-uterine devices (IUDs)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Previous pregnancy
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Positive attitude to family planning
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Better knowledge of family planning
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Lower education
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 879
Study: 29143803

Group type: EXPERIMENTAL
Intervention: High-protein diet (125 g protein/day) using novel functional foods
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional diet (80 g protein/day)
Number of subjects: 21
Study: 25351455

Group type: EXPERIMENTAL
Intervention: Pre-consultation educational group intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Routine education
Number of subjects: 41
Study: 23336160

Group type: EXPERIMENTAL
Intervention: INSURE method
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 64
Study: 22189641

Group type: EXPERIMENTAL
Intervention: GO adhesive system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adper SE Plus
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: OptiBond All‐In‐One
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clearfil 3S Bond
Number of subjects: 20
Study: 19702375

Group type: EXPERIMENTAL
Intervention: Frame-of-reference training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 0
Study: 16412769

Group type: EXPERIMENTAL
Intervention: GnRH antagonist plus recombinant luteinizing hormone
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard GnRH agonist flare-up protocol
Number of subjects: 133
Study: 15520321

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) combined with mild hypothermia (core temperature of 35 degrees C for 24 hours)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) combined with mild hypothermia
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo combined with mild hypothermia (core temperature of 35 degrees C for 24 hours)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo combined with mild hypothermia
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10)
Number of subjects: 49
Study: 11417474

Group type: EXPERIMENTAL
Intervention: Daunorubicin continuous infusion (CI) 60 mg/m2 days 2-4
Number of subjects: 77

Group type: COMPARATOR
Intervention: Bolus daunorubicin (30-min infusion) 60 mg/m2
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Daunorubicin continuous infusion (CI)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Bolus daunorubicin (30-min infusion)
Number of subjects: 77
Study: 9562303

Group type: EXPERIMENTAL
Intervention: Anti-neurofilament (NF) autoantibodies detected by ELISA in ALS patients
Number of subjects: 85

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 85

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Anti-NF antibodies in ALS patients
Number of subjects: 85
Study: 8179465

Group type: EXPERIMENTAL
Intervention: Desipramine (given for 2 days)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Desipramine (long-term treatment for 28 days)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Desipramine (long-term treatment)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (36 controls)
Number of subjects: 53
Study: 3068741

Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg three times a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 31732174

Group type: EXPERIMENTAL
Intervention: D + E
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: D
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: D and D + E
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Weight loss >10%
Number of subjects: 454
Study: 29858218

Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 22
Study: 27908500

Group type: EXPERIMENTAL
Intervention: Mental Skills Curriculum (MSC) during laparoscopic simulator training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (FLS training only)
Number of subjects: 60
Study: 25913081

Group type: EXPERIMENTAL
Intervention: TruView EVO2
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: TruView PCD
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Miller laryngoscope
Number of subjects: 78
Study: 22890587

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 30
Study: 21803405

Group type: EXPERIMENTAL
Intervention: 80 μg delprostenate
Number of subjects: 1131

Group type: EXPERIMENTAL
Intervention: 160 μg delprostenate
Number of subjects: 1131

Group type: EXPERIMENTAL
Intervention: PGF(2α) 7 d apart
Number of subjects: 1131

Group type: COMPARATOR
Intervention: PGF(2α) 8 d apart
Number of subjects: 1131

Group type: EXPERIMENTAL
Intervention: Synchrovine® with TAI at 42 h
Number of subjects: 1131

Group type: COMPARATOR
Intervention: AI 12 h after estrus detection
Number of subjects: 1131

Group type: EXPERIMENTAL
Intervention: Synchrovine® plus GnRH at TAI
Number of subjects: 1131

Group type: COMPARATOR
Intervention: AI following detection of spontaneous estrus
Number of subjects: 1131
Study: 19339374

Group type: EXPERIMENTAL
Intervention: Promotora + tailored newsletter
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Tailored newsletter only
Number of subjects: 238

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 238
Study: 16513871

Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Risperidone (2.5 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15479359

Group type: EXPERIMENTAL
Intervention: Silicone PEG tubes
Number of subjects: 138

Group type: COMPARATOR
Intervention: Polyurethane PEG tubes
Number of subjects: 138
Study: 10857527

Group type: EXPERIMENTAL
Intervention: Neurobehavioral Rating Scale‐Revised (NRS‐R)
Number of subjects: 286
Study: 9307345

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride (50-150 mg daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride
Number of subjects: 200
Study: 8665707

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Regular HME users
Number of subjects: 59
Study: 2693118

Group type: EXPERIMENTAL
Intervention: cromakalim (n = 12)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo (n = 6)
Number of subjects: 18
Study: 334132

Group type: EXPERIMENTAL
Intervention: Acetazolamide 63 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acetazolamide 125 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Acetazolamide 0 mg (control)
Number of subjects: 9
Study: 30946600

Group type: EXPERIMENTAL
Intervention: HR-guided management
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard transthoracic echocardiography-guided management
Number of subjects: 41
Study: 27417302

Group type: EXPERIMENTAL
Intervention: Education intervention (n=34)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Education and acceptance and commitment therapy intervention (n=39)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 73
Study: 25677598

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target systolic blood pressure <140 mm Hg)
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Guideline-based blood pressure management (systolic blood pressure <180 mm Hg)
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: IVH volume
Number of subjects: 2839
Study: 25143296

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 1839

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1839

Group type: EXPERIMENTAL
Intervention: Overall smoking cessation
Number of subjects: 1839

Group type: EXPERIMENTAL
Intervention: Overall smoking cessation (NRT participants)
Number of subjects: 1839
Study: 21993383

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 30
Study: 19282202

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (without GDM)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both GDM and control groups during head-up tilt (HUT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both GDM and control groups during pregnancy
Number of subjects: 79
Study: 18251162

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (VK2), 45 mg orally every day after therapy for HCC
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no VK2 treatment)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (VK2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Serum albumin concentration
Number of subjects: 45
Study: 15771794

Group type: EXPERIMENTAL
Intervention: Paraplatin dosage calculated according to body surface
Number of subjects: 54

Group type: COMPARATOR
Intervention: Paraplatin dosage calculated according to area under the curve (AUC)
Number of subjects: 54
Study: 12201623

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1600
Study: 9883316

Group type: EXPERIMENTAL
Intervention: IL-2 stimulation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: LPS stimulation (5 micrograms/ml)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (healthy patients)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: LPS stimulation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NDV stimulation (640 HU/ml)
Number of subjects: 26
Study: 8722434

Group type: EXPERIMENTAL
Intervention: Low salt diet (< 80 mmol/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: High salt diet (120 mmol of sodium chloride per day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low salt diet
Number of subjects: 34

Group type: COMPARATOR
Intervention: High salt diet
Number of subjects: 34
Study: 2048708

Group type: EXPERIMENTAL
Intervention: Group II (tourniquet applied after midazolam injection)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group I (tourniquet applied before midazolam injection)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group III (no tourniquet)
Number of subjects: 30
Study: 7044525

Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg p.o. twice daily)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (250 mg p.o. 4 times daily) with hydrocortisone (20 mg twice daily)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Combined tamoxifen and aminoglutethimide
Number of subjects: 117

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 117

Group type: COMPARATOR
Intervention: Aminoglutethimide
Number of subjects: 117
Study: 31670194

Group type: EXPERIMENTAL
Intervention: Resilience-focused intervention (training in small groups of 3-5 for six weeks, two times per week for 75 minutes)
Number of subjects: 122
Study: 31733764

Group type: EXPERIMENTAL
Intervention: Neural tensioning
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neural gliding
Number of subjects: 60
Study: 28223031

Group type: EXPERIMENTAL
Intervention: aripiprazole
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 141
Study: 25394826

Group type: EXPERIMENTAL
Intervention: Inhaled oxygen fraction (FiO₂) 1.0, 0.21, 0.15, and 0.10 with body positions (upright, supine, and 45° head down)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Severe hypoxia (FiO₂ = 0.10)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mouthpiece used during experimental trials
Number of subjects: 11
Study: 23870540

Group type: EXPERIMENTAL
Intervention: Web-based intervention website with information about the compensation process and a therapist-assisted problem-solving course
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control website with links to existing websites
Number of subjects: 176
Study: 21490143

Group type: EXPERIMENTAL
Intervention: ZnSuppl group (6 mg Zn added to the supplement dose)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (30 g dry weight of iron-fortified cereal porridge and a liquid multivitamin supplement without zinc)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: ZnFort group (zinc added to provide 6 mg Zn per 25 g dry weight of porridge and multivitamin without zinc)
Number of subjects: 137
Study: 19622294

Group type: EXPERIMENTAL
Intervention: Celecoxib plus surgery (200 mg twice daily for six days before surgery)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Surgery group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Celecoxib plus surgery group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 59
Study: 16671485

Group type: EXPERIMENTAL
Intervention: Hydrostatic shunt with an opening pressure of 50 mmH2O
Number of subjects: 123

Group type: COMPARATOR
Intervention: Hydrostatic shunt with an opening pressure of 100 mmH2O
Number of subjects: 123

Group type: COMPARATOR
Intervention: Hydrostatic shunt with an opening pressure of 130 mmH2O
Number of subjects: 123
Study: 15273527

Group type: EXPERIMENTAL
Intervention: Neuromuscular training program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Basic exercise training program
Number of subjects: 44
Study: 11510392

Group type: EXPERIMENTAL
Intervention: Water drops at body temperature, followed by a series of syringing attempts after 15 minutes.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oil as a dispersant for three days, followed by a series of syringing attempts after three days.
Number of subjects: 42
Study: 1334820

Group type: EXPERIMENTAL
Intervention: Double data entry (DE)
Number of subjects: 42278

Group type: COMPARATOR
Intervention: Single entry (SE)
Number of subjects: 42278
Study: 6373303

Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide
Number of subjects: 119

Group type: COMPARATOR
Intervention: 100 mg atenolol
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Switch to atenolol after non-response to hydrochlorothiazide
Number of subjects: 119

Group type: COMPARATOR
Intervention: Switch to hydrochlorothiazide after non-response to atenolol
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Combination therapy for non-responders
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 119
Study: 31801592

Group type: EXPERIMENTAL
Intervention: Directed evolution of ZfQQR zinc finger variants with optimized linker sequences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original ZfQQR zinc finger
Number of subjects: 0
Study: 30558396

Group type: EXPERIMENTAL
Intervention: Central European Diet (CED)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Mediterranean Diet (MED)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Comparison between CED and MED
Number of subjects: 144
Study: 29906360

Group type: EXPERIMENTAL
Intervention: rehabilitation exercises
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: manual lymphatic drainage
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: pneumatic compression pump
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: education only
Number of subjects: 44
Study: 24526709

Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS over the contralesional pars triangularis (PTr) for 10 sessions
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham 1-Hz stimulation
Number of subjects: 56
Study: 23253701

Group type: EXPERIMENTAL
Intervention: Standard-intensity warfarin (INR 2.1 to 2.5)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR 1.6 to 2.0)
Number of subjects: 786

Group type: COMPARATOR
Intervention: Aspirin (200 mg per day)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Standard-intensity warfarin
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin
Number of subjects: 786

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 786
Study: 20093151

Group type: EXPERIMENTAL
Intervention: Absolutely correct condition (100% correct)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Highly correct condition (80% correct)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Highly incorrect condition (20% correct)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Totally incorrect condition (0% correct)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Correct items
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Replaced items (related stimuli)
Number of subjects: 64
Study: 18338277

Group type: EXPERIMENTAL
Intervention: TENS (with superficial heat and exercise)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US) (with superficial heat and exercise)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (superficial heat and exercise)
Number of subjects: 45
Study: 15693730

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 139

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 139